<PAGE>
This is a confirming electronic copy of the Form 8-K
filed manually on May 24, 1995.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) May 17, 1995
------------------------------
OXIS INTERNATIONAL, INC.
- -------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-8092 94-1620407
- -------------------------------------------------------------------------------
(STATE OR OTHER (COMMISSION FILE NUMBER) (IRS EMPLOYER
JURISDICTION OF INCORPORATION) IDENTIFICATION NUMBER)
6040 N. Cutter Circle, Suite 317, Portland, OR 97217
- ------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
Registrant's telephone number, including area code. (503) 283-3911
---------------------------
- ------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
Total number of sequentially
numbered pages: 5
-----
Exhibit Index at page: 4
-----
<PAGE>
ITEM 5. OTHER EVENTS
------------
On May 17, 1995 and May 19, 1995, OXIS International, Inc. ("OXIS") sold
1,227,625 shares of its Common Stock in a private placement to offshore
investors for an aggregate consideration of $2,037,860. The Common Stock sold
is not registered under the Securities Act of 1933, as amended, and may not be
re-offered or re-sold absent registration under the Securities Act or available
exemptions from such registration requirements.
A copy of the Press Release with respect to such transaction is attached as
an exhibit to this report.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
------------------------------------------------------------------
(c) Exhibits
99.1 Press Release, dated May 19, 1995
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Oxis International, Inc.
(Registrant)
Dated: May 23, 1995 By: /s/ Ray R. Rogers
-- ---------------------
Name: Ray R. Rogers
Title: Chairman of the Board
<PAGE>
EXHIBIT INDEX
-------------
<TABLE>
<CAPTION>
Page No. in
sequentially numbered
Exhibit No. Description current report
----------- ----------- ---------------------
<S> <C> <C>
99.1 Press Release dated May 19, 1995 5
</TABLE>
<PAGE>
EXHIBIT 99.1
(BW) (OXIS-INTERNATIONAL-2) (OXIS) Oxis International Reports Private
Placement of Securities
Business Editors/Healthcare Writers
PORTLAND, Ore.--(BUSINESS WIRE)--May 19, 1995--OXIS International,
(NASDAQ:OXIS) announced today that it has raised $2,037,836 through a
private placement of 1,227,625 shares of common stock to Canadian and
European investors.
OXIS' Chairman, Ray R. Rogers, stated that the purpose of the
offering is principally to raise additional working capital to
continue research, development, and marketing programs. No other
terms of the transaction were disclosed.
The common stock sold has not been registered under the
Securities Act of 1933 and may not be reoffered or resold in the
United States absent registration or an applicable exemption from
such registration requirements.
OXIS International is a leading drug development and diagnostic
company dedicated to the research and development of antioxidants and
free radical scavengers to combat disease associated with excess free
radicals. The company, headquartered in Portland, Ore., has research
facilities in Mountain View, Calif. and near Paris, France.
--30--
CONTACT: OXIS International, Inc.
Ray R. Rogers, 503/283-3911
503/274-2165 (Before 9 a.m. PDT)
